Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd (VENMAX) last traded at ₹15.5, a market capitalisation of ₹22.4 crore, on a P/E of 80.2. Over the past 52 weeks the stock has ranged between ₹14.1 and ₹37. Venmax Drugs and Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹2.48 crore and net profit of ₹0.12 crore. Venmax Drugs and Pharmaceuticals Ltd’s annual general meeting is scheduled for 31 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Venmax Drugs and Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Venmax Drugs and Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2.48 cr, up 105.0% from ₹1.21 cr a year earlier. Net profit was ₹0.12 cr, up 200.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.17 | 0.2 | 0.33 | 1.21 | 1.32 | 1.55 | 3.94 | 2.48 |
| Expenses | 0.47 | 0.69 | 0.57 | 1.17 | 1.27 | 1.58 | 3.92 | 2.36 |
| Operating profit | -0.3 | -0.49 | -0.24 | 0.04 | 0.05 | -0.03 | 0.02 | 0.12 |
| OPM % | -176.47% | -245.00% | -72.73% | 3.31% | 3.79% | -1.94% | 0.51% | 4.84% |
| Other income | 0 | 0 | 1.02 | 0 | 0 | 0.07 | 0.09 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.3 | -0.49 | 0.78 | 0.04 | 0.05 | 0.04 | 0.11 | 0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 40.00% | 25.00% | 0.00% | 0.00% |
| Net profit | -0.3 | -0.5 | 0.78 | 0.04 | 0.02 | 0.03 | 0.11 | 0.12 |
| EPS (₹) | -0.57 | -0.95 | 1.49 | 0.08 | 0.02 | 0.04 | 0.09 | 0.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Venmax Drugs and Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0.17 | 0 | 0 | 0 | 0.81 | 8.02 | 9.29 |
| Operating profit | -0.33 | -0.12 | -0.19 | -0.11 | -0.93 | 0.12 | 0.16 |
| OPM % | -194.12% | — | — | — | -114.81% | 1.50% | 1.72% |
| Net profit | -0.16 | 1.85 | 0.23 | 0.06 | -0.01 | 0.25 | 0.28 |
| EPS (₹) | -0.31 | 3.53 | 0.44 | 0.11 | -0.02 | 0.22 | 0.25 |
TTM is the trailing twelve months to the most recent quarter.
Venmax Drugs and Pharmaceuticals Ltd growth and returns
- 10 Years
- 15%
- 5 Years
- 116%
- 3 Years
- %
- TTM
- 386%
- 10 Years
- 14%
- 5 Years
- 29%
- 3 Years
- 3%
- TTM
- 1300%
- 10 Years
- 20%
- 5 Years
- %
- 3 Years
- %
- 1 Year
- -56%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 3%
Venmax Drugs and Pharmaceuticals Ltd shareholding pattern
Promoters held 10.46% at Jun 2026, down from 23.13% at Jun 2025. DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 23.13% | 23.13% | 23.13% | 23.13% | 23.13% | 15.14% | 13.80% | 10.46% |
| DIIs | 0.15% | 0.15% | 0.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 76.72% | 76.72% | 76.71% | 76.87% | 76.86% | 84.86% | 86.21% | 89.53% |
| No. of shareholders | 6,291 | 6,657 | 6,756 | 6,729 | 6,764 | 6,815 | 6,802 | 6,865 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Venmax Drugs and Pharmaceuticals Ltd’s AGM?
Venmax Drugs and Pharmaceuticals Ltd’s annual general meeting is scheduled for 31 Aug 2026.
- AGMBoard meeting to approve notice and logistics for the 37th Annual General Meeting and regularize director appointments.
See the full results calendar for every Indian company reporting in the next 30 days.
Venmax Drugs and Pharmaceuticals Ltd corporate filings
- Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 ,inter alia, to consider and approve matters related ....Board Meetinglow impact
Cruxal's analysis: Venmax Drugs & Pharmaceuticals Limited has issued a routine regulatory intimation…
Read the full analysis - Newspaper Publication of the Unaudited Financial Results for the Quarter ended June 30, 2026.Company Updatelow impact
Cruxal's analysis: Venmax Drugs & Pharmaceuticals Limited has released its unaudited financial results for…
Read the full analysis - Statement of Deviation & Variation for the Quarter ended June 30, 2026.Company Updatelow impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Ltd has submitted its Statement of Deviation or…
Read the full analysis - Unaudited Standalone Financial Results along with the Limited Review Report For the Quarter ended June 30, 2026.Board Meetingmedium impact
Cruxal's analysis: Venmax Drugs and Pharmaceuticals Limited reported Q1 FY27 revenue from operations of 2.48…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Venmax Drugs and Pharmaceuticals Ltd
Cruxal reads every Venmax Drugs and Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.